📊 BBIO Key Takeaways
Is BridgeBio Pharma, Inc. (BBIO) a Good Investment?
BridgeBio exhibits severe financial distress with negative stockholders' equity of -$2.1B, indicating liabilities exceed assets by a significant margin. Despite 126% revenue growth, the company is deeply unprofitable with a -144.4% net margin and burning -$447M in free cash flow annually, raising serious questions about operational viability and cash runway.
BridgeBio Pharma is showing exceptional top-line growth, with revenue more than doubling year over year, which suggests meaningful commercial traction. However, that growth is not yet translating into sustainable fundamentals: operating and net margins remain deeply negative, free cash flow burn is severe, and the balance sheet is heavily burdened by debt and negative equity. The company has near-term liquidity, but overall financial health still looks weak until losses and cash burn improve materially.
Why Buy BridgeBio Pharma, Inc. Stock? BBIO Key Strengths
- Strong revenue growth of 126% YoY demonstrates market traction and commercial progress
- Adequate current ratio of 2.77x suggests near-term liquidity to cover immediate obligations
- Substantial cash position of $570.1M provides runway for operations and development
- Revenue growth is very strong at +126.3% YoY, indicating improving product or partnership traction
- Liquidity is currently adequate, with $570.12M in cash and a 2.77x current ratio
- Capital expenditure needs are minimal, which limits additional cash strain from fixed asset investment
BBIO Stock Risks: BridgeBio Pharma, Inc. Investment Risks
- Negative stockholders' equity of -$2.1B indicates capital structure distress and potential insolvency risk
- Operating cash burn of -$445.9M annually with negative free cash flow trajectory threatens long-term viability
- Net losses of -$724.9M with -144.4% net margin show business model is not generating sustainable profitability despite revenue growth
- Long-term debt of $2.0B combined with negative equity creates significant refinancing and default risk
- Deteriorating profitability per diluted EPS (-$3.78) despite revenue growth indicates inability to translate sales into value creation
- Profitability remains extremely weak, with a -104.2% operating margin and -144.4% net margin
- Balance sheet risk is elevated due to $3.01B in liabilities, $2.01B in long-term debt, and negative stockholders equity
- Cash generation is poor, with -$445.91M operating cash flow and -$447.01M free cash flow
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Path to operating profitability and EBITDA inflection
- Debt covenant compliance and refinancing requirements
- Gross margin expansion as revenue scales
- Working capital management and operating cash flow trends
- Operating cash burn relative to cash balance
- Progress in operating margin and net loss reduction
BridgeBio Pharma, Inc. (BBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.77x current ratio provides a solid financial cushion.
BBIO Profit Margin, ROE & Profitability Analysis
BBIO vs Healthcare Sector: How BridgeBio Pharma, Inc. Compares
How BridgeBio Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BridgeBio Pharma, Inc. Stock Overvalued? BBIO Valuation Analysis 2026
Based on fundamental analysis, BridgeBio Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BridgeBio Pharma, Inc. Balance Sheet: BBIO Debt, Cash & Liquidity
BBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BridgeBio Pharma, Inc.'s revenue has grown significantly by 620% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.95 indicates the company is currently unprofitable.
BBIO Revenue Growth, EPS Growth & YoY Performance
BBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.7M | -$164.3M | $-0.86 |
| Q2 2025 | $2.2M | -$75.5M | $-0.39 |
| Q1 2025 | $116.6M | -$36.2M | $-0.20 |
| Q3 2024 | $2.7M | -$164.3M | $-0.86 |
| Q2 2024 | $1.6M | -$75.5M | $-0.39 |
| Q1 2024 | $1.8M | -$36.2M | $-0.20 |
| Q3 2023 | $338.0K | -$140.2M | $-0.93 |
| Q2 2023 | $1.6M | -$2.6M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BridgeBio Pharma, Inc. Dividends, Buybacks & Capital Allocation
BBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BridgeBio Pharma, Inc. (CIK: 0001743881)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BBIO
What is the AI rating for BBIO?
BridgeBio Pharma, Inc. (BBIO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BBIO's key strengths?
Claude: Strong revenue growth of 126% YoY demonstrates market traction and commercial progress. Adequate current ratio of 2.77x suggests near-term liquidity to cover immediate obligations. ChatGPT: Revenue growth is very strong at +126.3% YoY, indicating improving product or partnership traction. Liquidity is currently adequate, with $570.12M in cash and a 2.77x current ratio.
What are the risks of investing in BBIO?
Claude: Negative stockholders' equity of -$2.1B indicates capital structure distress and potential insolvency risk. Operating cash burn of -$445.9M annually with negative free cash flow trajectory threatens long-term viability. ChatGPT: Profitability remains extremely weak, with a -104.2% operating margin and -144.4% net margin. Balance sheet risk is elevated due to $3.01B in liabilities, $2.01B in long-term debt, and negative stockholders equity.
What is BBIO's revenue and growth?
BridgeBio Pharma, Inc. reported revenue of $502.1M.
Does BBIO pay dividends?
BridgeBio Pharma, Inc. pays dividends, with $1.0M distributed to shareholders in the trailing twelve months.
Where can I find BBIO SEC filings?
Official SEC filings for BridgeBio Pharma, Inc. (CIK: 0001743881) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BBIO's EPS?
BridgeBio Pharma, Inc. has a diluted EPS of $-3.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BridgeBio Pharma, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BBIO stock overvalued or undervalued?
Valuation metrics for BBIO: ROE of N/A (sector avg: 15%), net margin of -144.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BBIO stock in 2026?
Our dual AI analysis gives BridgeBio Pharma, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BBIO's free cash flow?
BridgeBio Pharma, Inc.'s operating cash flow is $-445.9M, with capital expenditures of $1.1M. FCF margin is -89.0%.
How does BBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -144.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.77 (avg: 2).